{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2"},{"groupId":"OG001","value":"95.0"},{"groupId":"OG002","value":"98.2"},{"groupId":"OG003","value":"96.5"},{"groupId":"OG004","value":"98.7"},{"groupId":"OG005","value":"96.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"443"},{"groupId":"OG001","value":"459"},{"groupId":"OG002","value":"112"},{"groupId":"OG003","value":"114"},{"groupId":"OG004","value":"297"},{"groupId":"OG005","value":"312"}],"units":"Participants"}],"description":"An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.","groups":[{"description":"Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m\\^2), paclitaxel 175 mg/m\\^2, or docetaxel 75 mg/m\\^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.","id":"OG000","title":"Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)"},{"description":"Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.","id":"OG001","title":"Atezolizumab"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC2/3","id":"OG002","title":"IC2/3 Chemotherapy"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC2/3","id":"OG003","title":"IC2/3 Atezolizumab"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC1/2/3","id":"OG004","title":"IC1/2/3 Chemotherapy"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC1/2/3","id":"OG005","title":"IC1/2/3 Atezolizumab"}],"paramType":"NUMBER","populationDescription":"Safety analyses was performed on all randomized patients who received any amount of study treatment, with patients grouped according to whether any amount of atezolizumab was received including the case when atezolizumab was received in error.","reportingStatus":"POSTED","timeFrame":"Up to approximately 46 months after first participant enrolled","title":"Percentage of Participants With Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"percentage"}